Search research articles
Contact Us
Filters
Showing results (101-110 of 121) with videos related to
Page
of 13
Sort By:
Clinical Chemistry
|
October 1, 1996
Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples
R Dittadi, P Barioli, M Gion, et al.
European Urology
|
January 1, 1992
Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
S Omacini, R Mione, M Barichello, et al.
Breast Cancer Research and Treatment
|
January 1, 1996
Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters
A Piffanelli, R Dittadi, L Catozzi, et al.
Journal of the National Cancer Institute
|
January 15, 1997
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
G Gasparini, M Toi, M Gion, et al.
The Cancer Journal From Scientific American
|
April 13, 1999
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy
G Gasparini, M Toi, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 14, 2025
Redefining clinical trial strategic design to support drug approval in medical oncology
G Antonarelli, J M Pérez-García, M Gion, et al.
Tumori
|
November 1, 1996
Preliminary results of clinical evaluation of the free/total prostate-specific antigen ratio in a multicentric study
R Mione, G Aimo, E Bombardieri, et al.
Clinical Chemistry
|
December 4, 1998
Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions
M Gion, R Mione, P Barioli, et al.
The International Journal of Biological Markers
|
November 6, 1998
Prostate cancer probability after total PSA and percent free PSA determination
R Mione, P Barioli, M Barichello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 10, 2011
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)
C Pinto, F Di Fabio, E Maiello, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 121) with videos related to
Sort By:
Page
of 13
Clinical Chemistry
|
October 1, 1996
Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples
R Dittadi, P Barioli, M Gion, et al.
European Urology
|
January 1, 1992
Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
S Omacini, R Mione, M Barichello, et al.
Breast Cancer Research and Treatment
|
January 1, 1996
Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters
A Piffanelli, R Dittadi, L Catozzi, et al.
Journal of the National Cancer Institute
|
January 15, 1997
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
G Gasparini, M Toi, M Gion, et al.
The Cancer Journal From Scientific American
|
April 13, 1999
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy
G Gasparini, M Toi, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 14, 2025
Redefining clinical trial strategic design to support drug approval in medical oncology
G Antonarelli, J M Pérez-García, M Gion, et al.
Tumori
|
November 1, 1996
Preliminary results of clinical evaluation of the free/total prostate-specific antigen ratio in a multicentric study
R Mione, G Aimo, E Bombardieri, et al.
Clinical Chemistry
|
December 4, 1998
Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions
M Gion, R Mione, P Barioli, et al.
The International Journal of Biological Markers
|
November 6, 1998
Prostate cancer probability after total PSA and percent free PSA determination
R Mione, P Barioli, M Barichello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 10, 2011
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)
C Pinto, F Di Fabio, E Maiello, et al.
Page
of 13